ePrints

Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group

Lookup NU author(s): Steven White

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background: Most resectable pancreatic cancers are classified as T3, including those involving the porto-mesenteric vein. Survival and periopetative morbidity for venous resection have been found to be comparable to standard resection. We investigate factors associated with short and long term outcomes in pancreaticoduodenectomy with (PDVR) and without (PD) venous resection exclusively for T3 adenocarcinoma of the head of the pancreas.Methods: This is a UK multicenter retrospective cohort study assessing outcomes in patients undergoing PD and PDVR. All consecutive patients with T3 only adenocarcinoma of the head of the pancreas undergoing surgery between December 1998 and June 2011 were included. Multivariable logistic and proportional hazards regression analyses were performed to determine the association between the surgical groups and in-hospital mortality (IHM) and overall survival (OS).Results: 1070 patients were included of whom 840 (78.5%) had PD and 230 (21.5%) had PDVR. Factors independently associated with IHM were a high creatinine (aHR 1.14, p = 0.02), post-operative bleeding (aHR 2.86, p = 0.04) and a re-laparotomy (aHR 8.42, p = 0.0001). For OS, multivariable analyses identified R1 resection margin status (aHR 1.22, p = 0.01), N1 nodal status (aHR 1.92, p = 0.0001), perineural invasion (aHR 1.37, p = 0.002), tumour size >20mm (aHR 0.63, p = 0.0001) and a relaparotomy (aHR 1.84, p = 0.0001) to be independently associated with overall mortality.Conclusion: This study on T3 adenocarcinoma of the head of the pancreas suggests that Mil is strongly associated with perioperative complications whilst OS is affected by histological parameters. Detailed pre-operative disease evaluation and advances in oncological treatment have the potential to improve OS. (C) 2015 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Elberm H, Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, Bond-Smith G, Bramhall S, Coldham C, Hammond J, Hutchins R, Imber C, Preziosi G, Saleh A, Silva M, Simpson J, Spoletini G, Stell D, Terrace J, White S, Wigmore S, Fusai G

Publication type: Article

Publication status: Published

Journal: European Journal of Surgical Oncology

Year: 2015

Volume: 41

Issue: 11

Pages: 1500-1507

Print publication date: 01/11/2015

Online publication date: 28/08/2015

Acceptance date: 04/08/2015

ISSN (print): 0748-7983

ISSN (electronic): 1532-2157

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.ejso.2015.08.158

DOI: 10.1016/j.ejso.2015.08.158

Altmetrics

Share